BioMS Medical Corp., of Edmonton, Alberta, appointed John Wetherell to the board of its subsidiary, Rycor Technology Investments Corp.
Eos Biotechnology Inc., of South San Francisco, appointed Robert Williamson president and chief operating officer.
EpiCept Corp., of Englewood Cliffs, N.J., added Howard Maibach and Misha-Miroslav Backonja to its board of scientific and medical advisers.
Genome Therapeutics Corp., of Waltham, Mass., added Timothy Leach as vice president of clinical and medical affairs.
Immunomedics Inc., of Morris Plains, N.J., appointed Ivan Horak executive vice president of research and development.
Inologic Inc., of Seattle, appointed Bea Langton-Webster vice president, drug development, and Edward Field president and director.
InterMune Inc., of Brisbane, Calif., appointed Marianne Armstrong senior vice president, global regulatory operations and corporate compliance, and promoted Bradley Scates to vice president, finance.
Metabolex Inc., of Hayward, Calif., appointed Randolph Soltys vice president of preclinical development.
MorphoSys AG, of Munich, Germany, appointed Claudia Gutjahr-Loeser manager, corporate communications, and Alexander Oehmichen general counsel.
Protarga Inc., of King of Prussia, Pa., appointed Frank Bambarola vice president, oncology, and Timothy McKinlay senior director, clinical operations.